Drugs that contain Apomorphine Hydrochloride
1. Kynmobi patents expiration
KYNMOBI's oppositions filed in EPO
KYNMOBI Litigations
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9931305 | SUMITOMO PHARMA AM | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
Feb, 2022
(2 years ago) | |
| US9855221 | SUMITOMO PHARMA AM | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
Feb, 2022
(2 years ago) | |
| US10888499 | SUMITOMO PHARMA AM | Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom |
Feb, 2022
(2 years ago) | |
| US11077068 | SUMITOMO PHARMA AM | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
Feb, 2022
(2 years ago) | |
| US8663687 | SUMITOMO PHARMA AM | Film compositions for delivery of actives |
Feb, 2023
(1 year, 2 months ago) | |
| US8765167 | SUMITOMO PHARMA AM | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
Feb, 2024
(a month ago) | |
| US8603514 | SUMITOMO PHARMA AM | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
Apr, 2024
(16 days ago) | |
| US10821074 | SUMITOMO PHARMA AM | Sublingual and buccal film compositions |
Aug, 2029
(5 years from now) | |
| US9669019 | SUMITOMO PHARMA AM | Sublingual apomorphine |
Jun, 2030
(6 years from now) | |
| US9283219 | SUMITOMO PHARMA AM | Sublingual films |
Jun, 2030
(6 years from now) | |
| US9326981 | SUMITOMO PHARMA AM | Sublingual apomorphine |
Jun, 2030
(6 years from now) | |
| US9044475 | SUMITOMO PHARMA AM | Sublingual apomorphine |
Jun, 2030
(6 years from now) | |
| US10420763 | SUMITOMO PHARMA AM | Sublingual apomorphine |
Jun, 2030
(6 years from now) | |
| US9669021 | SUMITOMO PHARMA AM | Sublingual apomorphine |
Jun, 2030
(6 years from now) | |
| US8846074 | SUMITOMO PHARMA AM | Sublingual films |
Dec, 2031
(7 years from now) | |
| US8414922 | SUMITOMO PHARMA AM | Sublingual films |
Dec, 2031
(7 years from now) | |
| US11419769 | SUMITOMO PHARMA AM | Sublingual films |
Dec, 2031
(7 years from now) | |
| US10959943 | SUMITOMO PHARMA AM | Methods of treating Parkinson's disease by administration of apomorphine to an oral mucosa |
Apr, 2036
(12 years from now) | |
| US10449146 | SUMITOMO PHARMA AM | Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa |
Apr, 2036
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 21, 2023 |
Market Authorisation Date: 21 May, 2020
Treatment: Treatment of 'off' episodes in patients with parkinson's disease
Dosage: FILM;SUBLINGUAL
More Information on Dosage
KYNMOBI family patents
